New hope for Hard-to-Treat breast cancer? study cut short
NCT ID NCT05954143
First seen Nov 20, 2025 · Last updated May 13, 2026 · Updated 18 times
Summary
This study tested a new drug called BDC-1001, given alone or with another drug (pertuzumab), in people with advanced HER2-positive breast cancer that had already been treated with several therapies, including trastuzumab deruxtecan. The goal was to see if the drug could shrink tumors. However, the study was stopped early after enrolling only 11 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Irvine, California, 92618, United States
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Virginia Cancer Specialists
Arlington, Virginia, 22205, United States
Conditions
Explore the condition pages connected to this study.